New research in coenzyme Q10 and selenium
In 2012 a large scale Swedish study was published in an international cardiovascular journal. Kisel-10 as the study is named showed the results of four years intake of Pharma Nords selenium and CoQ10 preparations in 444 seniors between 70 and 88 years of age.
This double blinded and placebo controlled study showed that the group who received CoQ10 and selenium was doing remarkably better than the group who received placebo. The preventive effect was visible in a series of medical conditions as well as in quality of life markers.
Likewise, in 2014 the Q-Symbio study showed a clear difference between patients who received Pharma Nord's CoQ10 preparation and patients who received placebo. The study was a multi center study conducted in thirteen hospitals in nine different countries and is one of the largest studies ever conducted on coenzyme Q10. The study was published in JACC: , one of the most renowned cardiovascular journals in the world.
In 2018, researcher Stefano Giannubilo published a study on age-related infertility in women between ages of 31 and 46. These women received 100mg of CoQ10 twice daily. The result has led researchers to the conclusion that oral supplementation with CoQ10 is suitable for women over the age of 35 years experiencing age-related infertility.
In 2019, Professor Professors Lopez-Lluch and colleagues in Spain conducted a study that showed superior absorption of Pharma Nord's CoQ10 preparation with ubiquinone and that the entire manufacturing process including the selection of oils and treatment of the CoQ10 raw material is more important for the absorption of different CoQ10 than the form (ubiquinone or ubiquinol ) CoQ10 comes in.